A nationwide partnership brought together in the early stages of the COVID-19 pandemic to accelerate how quickly promising COVID-19 diagnostics make it into real-world use.
A single route to evaluate new diagnostic tests for COVID-19
Researchers from the NIHR Community Health Care MedTech and In Vitro Diagnostics Co-operative were key in helping to bring about and execute the CONDOR platform.
The CONDOR platform is comprised of six different studies all aiming to accelerated how quickly promising COVID-19 diagnostics make it into real-world use. The platform is evaluating new COVID-19 diagnostics in the settings they will be used, such as in GP surgeries, care homes, or hospitals, as well as their performance in laboratory settings.
These tests will be used to support diagnosis and management of patients with suspected COVID-19, and collect data to help develop effective diagnostic pathways for subsequent waves of infection in the post-pandemic setting.
The platform comprises a number of partners, including Manchester University NHS Foundation Trust's Diagnostic and Technology Accelerator (DiTA), and NIHR MedTech and In Vitro Diagnostics Co-operatives (MICs) based in Oxford, Leeds, London and Newcastle.
CONDOR is funded by UK Research and Innovation, the Department of Health and Social Care through the National Institute for Health Research, Asthma UK and the British Lung Foundation.
Are diagnostic tests cost-effective? Modified assessment checklist produced
8 January 2019
A diagnostic test-specific checklist to assess decision modelling has been developed and piloted.
Analysis of community blood test requests highlights potential demand for multiplex platforms
21 September 2018
A team from the NIHR Community Healthcare MIC analysed data from over 11.7 million laboratory blood tests.